2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-163027
    R079 2115659-62-4 98%
    R079 (compound 17) is a selective, orally active Nrf2 activator. R079 increases Nrf2 translocation activity (EC50 = 32.41 μM). R079 can neutralize excess levels of reactive oxygen species through activating Nrf2. R079 has anti-inflammatory properties and can be used in multiple sclerosis research .
    R079
  • HY-163036
    Glucosamine–biotin adduct 1825360-98-2 98%
    Glucosamine-biotin adduct is a hapten and can be conjugated to hsIgG.
    Glucosamine–biotin adduct
  • HY-163037
    Pseudo-β-D-mannopyranose 90694-07-8 98%
    Pseudo-β-D-mannopyranose is a hapten that can be coupled with mannose.
    Pseudo-β-D-mannopyranose
  • HY-163040
    DOTA-Tyr-Lys-DOTA 2757339-62-9 98%
    DOTA-Tyr-Lys-DOTA is a DOTA-based small molecule hapten. DOTA-Tyr-Lys-DOTAexhibits rapid clearance and low whole-body retention. DOTA-Tyr-Lys-DOTA can used in study pretargeted radioimmunotherapy.
    DOTA-Tyr-Lys-DOTA
  • HY-163045
    4-Azidophenylarsonic acid 861605-27-8 98%
    4-Azidophenylarsonic acid, a Hapten that contains a diazonium group, is a probes of antibody response and immunorecognition.
    4-Azidophenylarsonic acid
  • HY-163061
    Quinotolast 101193-40-2 98%
    Quinotolast is an orally active antiallergic agent. Quinotolast inhibits histamine release from rat peritoneal cells. Quinotolast inhibits cutaneous cromoglycate in guinea pig model. Quinotolast has inhibitory effect on histamine and peptide leukotrienes release from guinea pig lung fragments and mouse cultured mast cells. Quinotolast can be studied in allergy-related research.
    Quinotolast
  • HY-163091
    EP4 receptor antagonist 5 98%
    EP4 receptor antagonist 5 is a potent and selective prostanoid EP4 receptor antagonist that can reduce inflammation Freund’s adjuvant (CFA) model.
    EP4 receptor antagonist 5
  • HY-163116
    Anti-inflammatory agent 67 98%
    Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonic anhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII).
    Anti-inflammatory agent 67
  • HY-163117
    Anti-inflammatory agent 68 98%
    Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonic anhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonic anhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII).
    Anti-inflammatory agent 68
  • HY-163128
    SPL-IN-1 353770-24-8 98%
    SPL-IN-1 (compound C17) is a dual species sphingosine-1-phosphate lyase inhibitor.
    SPL-IN-1
  • HY-163151
    JE-133 2579171-69-8 98%
    JE-133 is an optically active isochromane-2H-chromene conjugate. JE-133 exhibits antioxidant and anti-inflammatory activities. JE-133 is a neuroprotective agent that effectively inhibits neuronal oxidative damage associated with PI3K/Akt and MAPK signaling pathways. JE-133 can also inhibit lipopolysaccharide (LPS) (HY-D1056)-induced neuroinflammation by regulating JAK/STAT and Nrf2 signaling pathways.
    JE-133
  • HY-163162
    Anhydro-Ouabain 3029806-33-2 98%
    Anhydro-Ouabain (compound 20) is a cardiotonic steroid which shows anti-inflammatory and neuroprotective activities and thus can be used in neurological research.
    Anhydro-Ouabain
  • HY-163183
    JAK3/BTK-IN-7 2844387-16-0 98%
    JAK3/BTK-IN-7 (XL-12) is a JAK3/BTK inhibitor with IC50 values of 2 nM and 14 nM, respectively. JAK3/BTK-IN-7 has anti-inflammatory activity and can be used in the study of rheumatoid arthritis.
    JAK3/BTK-IN-7
  • HY-163187
    COX-2/LOX-IN-1 98%
    COX-2/LOX-IN-1 (compound 5) is a dual cyclooxygenase-2/lipoxygenase (COX-2/LOX) inhibitor with IC50s of 30 μM and 0.55 μM, for LOX and COX-2, respectively. .
    COX-2/LOX-IN-1
  • HY-163188
    COX-2/LOX-IN-2 98%
    COX-2/LOX-IN-2 (compound 6) is a dual inhibitor of COX-2/LOX with IC50s of 7.0 μM and 27.5 μM, respectively. COX-2/LOX-IN-2 has antioxidant activity and has the potential to be used in the development of nonsteroidal anti-inflammatory drugs (tNSAIDs).
    COX-2/LOX-IN-2
  • HY-163271
    XL-126 3033576-12-1 98%
    XL-126 (Compound 33) is a potent BD1-selective BET inhibitor, with a Kd of 8.9 nM. XL-126 leads to both the preservation of platelets and potent anti-inflammatory efficacy by BD1 selectivity.
    XL-126
  • HY-163274
    NOD1 antagonist-1 3030588-37-2 98%
    NOD1 antagonist-1 (compound 37) exhibits an antagonistic activity towards NOD1 and a weak NOD1/NOD2 selectivity, with IC50s of 9.18 μM and 20.8 μM, respectively.
    NOD1 antagonist-1
  • HY-163277
    PIPE-3297 98%
    PIPE-3297 (compound 25) is a selective kappa opioid receptor (KOR) agonist, which activates the G-protein signaling with EC50 of 1.1 nM and exhibits low β-arrestin-2 recruitment activity (10%). PIPE-3297 induces myelination and reveals an anti-inflammatory activity.
    PIPE-3297
  • HY-163300
    NLRP3-IN-30 98%
    NLRP3-IN-30 (Compound A14) is a potent NLRP3 inhibitor, with an IC50 of 44.43 nM. NLRP3-IN-30 has highly oral bioavailability (F is 83.09% in mice).
    NLRP3-IN-30
  • HY-163303
    Tyk2-IN-15 3010873-44-3 98%
    Tyk2-in-15 (Compound 97) is a selective tyrosine kinase 2 (Tyk2) inhibitor with IC50 value ≤ 10 nM for Tyk2-JH2. Tyk2-IN-15 can be used in the study of inflammatory or autoimmune diseases.
    Tyk2-IN-15
製品番号 製品名 / Synonyms Application Reactivity